US2012093913A1PendingUtilityA1
Inhibition of SYK kinase expression
Individually held — no corporate assignee on recordPriority: Jul 3, 2003Filed: May 3, 2011Published: Apr 19, 2012
Est. expiryJul 3, 2023(expired)· nominal 20-yr term from priority
A61P 37/02A61P 43/00A61P 7/04A61P 7/06A61P 29/00A61P 27/02A61P 13/10C12N 2310/14C12N 15/1137A61P 11/00C12Y 207/10001A61P 17/00
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small interfering RNA (siRNA).
Claims
exact text as granted — not AI-modified1 . A method of inhibiting expression of Syk kinase in a cell comprising introducing into said cell small interfering RNA (siRNA) molecules that direct cleavage of a target Syk kinase mRNA sequence present in said cell thereby effecting said inhibition.
2 . The method according to claim 1 wherein said siRNA molecules are about 20-23 nucleotides in length.
3 . The method according to claim 1 wherein said siRNA molecules are introduced directly into said cell.
4 . The method according to claim 1 wherein said siRNA molecules are produced intracellularly following introduction into said cell a nucleotide sequence encoding said siRNA molecule.
5 . The method according to claim 1 wherein said siRNA molecules comprise two strands, and at least 1 strand of said siRNA molecules has a 3′ overhang of about 1 to about 6 nucleotides in length.
6 . The method according to claim 5 wherein both strands of said siRNA molecules have 3′ overhangs of about 2 to 3 nucleotides in length.
7 . The method according to claim 6 wherein said 3′ overhangs comprise uridines or thymidines.
8 . The method according to claim 1 wherein said siRNA molecules have a stem loop structure.
9 . The method according to claim 8 wherein the 3′ end of said stem loop structure has a 3′ overhang of about 1 to about 6 nucleotides in length.
10 . The method according to claim 9 wherein said 3′ overhang is about 2 to about 3 nucleotides in length.
11 . The method according to claim 1 wherein said target sequence is a sequence unique to Syk kinase mRNA.
12 . The method according to claim 11 wherein said target sequence (expressed as the cDNA) comprises a nucleotide sequence selected from the group consisting of:
AATATGTGAAGCAGACATGGA,
AATCAAATCATACTCCTTCCC,
AAGAGAGTACTGTGTCATTCA,
AAGGAAAACCTCATCAGGGAA,
AATCATACTCCTTCCCAAAGC,
AATTTTGGAGGCCGTCCACAA,
AAGACTGGGCCCTTTGAGGAT,
AAGCAGACATGGAACCTGCAG,
AACTTCCAGGTTCCCATCCTG,
AAGCCTGGCCACAGAAAGTCC,
AAGCCCTACCCATGGACACAG,
AACCTGCAGGGTCAGGCTCTG,
AAGGGGTGCAGCCCAAGACTG,
AACTTGCACCCTGGGCTGCAG,
AAGTCCTCCCCTGCCCAAGGG,
AAGGCCCCCAGAGAGAAGCCC,
AATCTCAAGAATCAAATCATA,
AATGTTAATTTTGGAGGCCGT,
AATCCGTATGAGCCAGAACTT,
AATCGGCACACAGGGAAATGT,
AACCGGCAAGAGAGTACTGTG,
AAGGAGGTTTACCTGGACCGA,
and
AACCTCATCAGGGAATATCTG.
13 . The method according to claim 1 wherein said cell is a mammalian cell.
14 . The method according to claim 13 wherein said cell is a human cell.
15 . The method according to claim 14 wherein said cell is present in a human.
16 . The method according to claim 15 wherein said human is a patient suffering from an inflammatory condition and said siRNA molecules are administered in an amount sufficient to effect treatment of said condition.
17 . The method according to claim 16 wherein said inflammatory condition is a condition of the bronchi, lungs, eyes; bladder or skin of said patient.
18 . The method according to claim 17 wherein said inflammatory condition is a condition of the bronchi or lungs and said siRNA molecules are introduced into bronchi or lung cells by inhalation.
19 . An siRNA molecule comprising a sequence complementary to a sequence selected from the group consisting of:
AATATGTGAAGCAGACATGGA,
AATCAAATCATACTCCTTCCC,
AAGAGAGTACTGTGTCATTCA,
AAGGAAAACCTCATCAGGGAA,
AATCATACTCCTTCCCAAAGC,
AATTTTGGAGGCCGTCCACAA,
AAGACTGGGCCCTTTGAGGAT,
AAGCAGACATGGAACCTGCAG,
AACTTCCAGGTTCCCATCCTG,
AAGCCTGGCCACAGAAAGTCC,
AAGCCCTACCCATGGACACAG,
AACCTGCAGGGTCAGGCTCTG,
AAGGGGTGCAGCCCAAGACTG,
AACTTGCACCCTGGGCTGCAG,
AAGTCCTCCCCTGCCCAAGGG,
AAGGCCCCCAGAGAGAAGCCC,
AATCTCAAGAATCAAATCATA,
AATGTTAATTTTGGAGGCCGT,
AATCCGTATGAGCCAGAACTT,
AATCGGCACACAGGGAAATGT,
AACCGGCAAGAGAGTACTGTG,
AAGGAGGTTTACCTGGACCGA,
and
AACCTCATCAGGGAATATCTG.
20 . A composition comprising the siRNA molecule according to claim 19 and a carrier.
21 . A composition comprising the siRNA molecule according to claim 19 and a liposome or polymer.Join the waitlist — get patent alerts
Track US2012093913A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.